The Supreme Court on Friday granted the HIV-prevention field a historic win — yet with a major caveat — as it upheld a ...

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

The FDA approved Gilead's HIV prevention drug lenacapavir, ... The drug will be marketed under the name Yeztugo and sell for an annual price of $28,218, or $14,109 per injection.

The FDA has approved Yeztugo, the first long-acting injectable PrEP shot, which could significantly impact HIV prevention ...